NCT02972385 Pharmacogenomics of Warfarin in Hispanics and Latinos
| NCT ID | NCT02972385 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arizona |
| Condition | Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2016-09 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2016-09 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin. Certain genes have also been found to affect warfarin dose. Individuals have variations in these genes, which can help explain why some patients need higher dose and others require less. These factors have been used to better predict a patient's warfarin dose requirement. However, these predictions were created based on Caucasian populations and they may not be accurate in predicting a safe warfarin dose if a patient is not Caucasian. This study aims to identify new genetic variation that affects warfarin dosing in Hispanic and Latino populations and try to better predict a Hispanic or Latino patient's warfarin dose requirement.
Eligibility Criteria
Inclusion Criteria: * At least 18 years of age * Ability to give informed consent * Therapeutic INR for at least 2 consecutive clinic visits * Self-identifies as Hispanic or Latino Exclusion Criteria: * Less than 18 years old * Unable to give informed consent * Severe hepatic impairment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02972385 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02972385 currently recruiting?
Yes, NCT02972385 is actively recruiting participants. Contact the research team at karnes@pharmacy.arizona.edu for enrollment information.
Where is the NCT02972385 trial being conducted?
This trial is being conducted at Tucson, United States.
Who is sponsoring the NCT02972385 clinical trial?
NCT02972385 is sponsored by University of Arizona. The trial plans to enroll 400 participants.